Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration.

Sanofi (NASDAQ:SNY)’s shares fell 5% this week, even as the company announced positive results from its AERIFY-1 trial with ...

According to the Vietnam Administration of Disease Prevention, in the 40 years of organising and implementing the National Expanded Programme on Immunisation since 1985, Vietnam has achieved several ...

Sublime’s award is just one of the 24 that were rolled back after U.S. Secretary of Energy Chris Wright announced the awards ...

Sanofi's $470M Vigil Neuroscience, Inc. acquisition highlights VG-3927's potential in Alzheimer's. Click here to find out why ...

This week on "The Readout LOUD" podcast: an AI experiment at the FDA and how Novo Nordisk is trailing in the obesity drug ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

The acquisition includes a rare immunology disease medicine and an advanced and early-stage immunology pipeline.

The investment includes a significant boost to research and development and the expansion of partnerships with domestic ...

DEPARTMENT OF JUSTICE NEWS RELEASE Attorney General Raúl Torrez announced settlements with two major insulin ...

The attorney general described the agreements as "huge wins" for New Mexico, which is home to more than 200,000 adults with ...

Sanofi announced that it will buy pharma company Blueprint Medicines for $129 per share, making the deal worth more than $9 ...